SARS-CoV-2: A Liver Brief

Area of Science:

• Molecular and Cellular Physiology
• Infectious Diseases

Background:

• COVID-19 pandemic caused by SARS-CoV-2 leads to multi-organ damage, notably liver injury.
• Mechanisms of liver dysfunction involve direct viral infection, immune responses (cytokine storm), and the gut-liver axis.
• Pre-existing liver conditions like MAFLD, ALD, and fibrosis increase COVID-19 severity.

Purpose of the Study:

• Explore the molecular mechanisms of liver dysfunction in COVID-19 patients.
• Investigate viral entry pathways into liver cells.
• Understand the impact of immune responses and pre-existing conditions on COVID-19 liver injury.

Main Methods:

• Review of molecular mechanisms of SARS-CoV-2 entry into hepatocytes.
• Analysis of immune-mediated liver damage pathways.
• Examination of the role of the gut-liver axis in COVID-19 pathogenesis.

Main Results:

• SARS-CoV-2 utilizes ACE2/TMPRSS2 and alternative receptors (DC-SIGN, AXL) for liver cell entry.
• Immune responses, particularly cytokine storm, significantly contribute to hepatocyte damage.
• Pre-existing liver diseases exacerbate COVID-19 outcomes.
• Post-COVID-19 complications include fibrosis progression and persistent liver damage.
• Drug-Induced Liver Injury (DILI) is a concern with COVID-19 treatments.

Conclusions:

• Understanding SARS-CoV-2-induced liver injury is crucial for patient outcomes.
• Targeted therapies are needed to mitigate liver complications in acute and Long COVID-19.
• Further research into chronic inflammation, viral persistence, and autoimmune reactions post-COVID-19 is warranted.